These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 14616825)

  • 21. Efficacy and safety of etanercept in chronic immune-mediated disease.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Magnani O; Puppo F
    Expert Opin Drug Saf; 2014 May; 13(5):649-61. PubMed ID: 24654562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infliximab-induced discoid lupus erythematosus.
    Cemil BC; Atas H; Canpolat F; Akca Y; Sasmaz R
    Lupus; 2013 Apr; 22(5):515-8. PubMed ID: 23554040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept.
    Mor A; Bingham CO; Barisoni L; Lydon E; Belmont HM
    J Rheumatol; 2005 Apr; 32(4):740-3. PubMed ID: 15801034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case of tuberculous arthritis following the use of etanercept.
    Choi SW; Ahn JJ; Hwang YT; Koh SH; Cho SD
    Korean J Intern Med; 2009 Dec; 24(4):397-401. PubMed ID: 19949742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dermatological complications of etanercept therapy for rheumatoid arthritis.
    Misery L; Perrot JL; Gentil-Perret A; Pallot-Prades B; Cambazard F; Alexandre C
    Br J Dermatol; 2002 Feb; 146(2):334-5. PubMed ID: 11903255
    [No Abstract]   [Full Text] [Related]  

  • 26. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
    Tobin AM; Kirby B
    BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
    Exarchou SA; Voulgari PV; Markatseli TE; Zioga A; Drosos AA
    Scand J Rheumatol; 2009; 38(5):328-31. PubMed ID: 19579151
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of infliximab-induced lupus in a patient with ankylosing spondylitis: is it safe switch to another anti-TNF-α agent?
    Santiago T; Santiago MG; Rovisco J; Duarte C; Malcata A; da Silva JA
    Clin Rheumatol; 2013 Dec; 32(12):1819-22. PubMed ID: 23955767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis.
    Cho SK; Oh IH; Park CK; Bae SC; Sung YK
    Rheumatol Int; 2012 Apr; 32(4):1055-7. PubMed ID: 20062996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents.
    Haraoui B; Keystone E
    Curr Opin Rheumatol; 2006 Jan; 18(1):96-100. PubMed ID: 16344625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
    Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
    Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature.
    Shovman O; Tamar S; Amital H; Watad A; Shoenfeld Y
    Clin Rheumatol; 2018 Feb; 37(2):563-568. PubMed ID: 29063464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.
    Jarrett SJ; Cunnane G; Conaghan PG; Bingham SJ; Buch MH; Quinn MA; Emery P
    J Rheumatol; 2003 Oct; 30(10):2287-91. PubMed ID: 14528531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN; Battafarano DF
    Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients.
    Cavazzana I; Bobbio-Pallavicini F; Franceschini F; Bazzani C; Ceribelli A; Bravi E; Zingarelli S; Caporali R; Cattaneo R; Montecucco CM
    Clin Exp Rheumatol; 2007; 25(5):676-83. PubMed ID: 18078613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of rheumatoid arthritis with etanercept.
    Genovese MC; Kremer JM
    Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-induced systemic lupus erythematosus and TNF-alpha blockers.
    Mohan AK; Edwards ET; Coté TR; Siegel JN; Braun MM
    Lancet; 2002 Aug; 360(9333):646. PubMed ID: 12241965
    [No Abstract]   [Full Text] [Related]  

  • 40. Etanercept in arthritis.
    Scott DL
    Int J Clin Pract; 2005 Jan; 59(1):114-8. PubMed ID: 15707475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.